Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications

Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1080-H1083. doi: 10.1152/ajpheart.00215.2020. Epub 2020 Mar 30.

Authors

Zaid Abassi^{1

2}, Suheir Assady³, Emad E Khoury¹, Samuel N Heyman⁴

Affiliations

¹ Department of Physiology and Biophysics, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
² Laboratory Medicine, Rambam Health Care Campus, Haifa, Israel.
³ Department of Nephrology and Hypertension, Rambam Health Care Campus, Haifa, Israel.
⁴ Department of Medicine, Hadassah Hebrew University Hospital, Mount Scopus, Jerusalem, Israel.

No abstract available

Publication types

Letter

MeSH terms

Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Betacoronavirus / metabolism*
COVID-19
Cardiovascular Diseases / enzymology*
Cardiovascular Diseases / virology*
Coronavirus Infections / complications*
Coronavirus Infections / enzymology
Coronavirus Infections / metabolism*
Coronavirus Infections / virology
Humans
Myocardium / enzymology
Myocardium / metabolism
Pandemics
Peptidyl-Dipeptidase A / biosynthesis
Peptidyl-Dipeptidase A / metabolism*
Pneumonia, Viral / complications*
Pneumonia, Viral / enzymology
Pneumonia, Viral / metabolism*
Pneumonia, Viral / virology
SARS-CoV-2

Substances

Angiotensin-Converting Enzyme Inhibitors
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2